Provided by Tiger Trade Technology Pte. Ltd.

Korro Bio, Inc.

10.40
-0.5100-4.67%
Post-market: 10.400.00000.00%16:10 EDT
Volume:127.09K
Turnover:1.33M
Market Cap:149.99M
PE:-0.83
High:10.87
Open:10.80
Low:10.25
Close:10.91
52wk High:55.89
52wk Low:5.20
Shares:14.42M
Float Shares:10.20M
Volume Ratio:0.78
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4806
EPS(LYR):-12.4806
ROE:-110.70%
ROA:-32.14%
PB:2.92
PE(LYR):-0.83

Loading ...

Korro Bio Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
Jan 29

Korro Bio upgraded to Buy from Neutral at Chardan

TIPRANKS
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Pfizer (PFE) and Alpha Teknova (TKNO)

TIPRANKS
·
Jan 29

U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio

Reuters
·
Jan 29

Korro Bio Inc : Piper Sandler Raises to Overweight From Neutral; Raises Target Price to $30 From $11

THOMSON REUTERS
·
Jan 29

Korro Bio upgraded to Overweight from Neutral at Piper Sandler

TIPRANKS
·
Jan 29

Korro Bio Raised to Overweight From Neutral by Cantor Fitzgerald

Dow Jones
·
Jan 28

Analysts Conflicted on These Healthcare Names: Korro Bio (KRRO), Kazia Therapeutics (KZIA) and AbbVie (ABBV)

TIPRANKS
·
Jan 28

Korro Bio : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
Jan 28

Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald

TIPRANKS
·
Jan 28

Korro Bio price target raised to $10 from $7 at Clear Street

TIPRANKS
·
Jan 28

Korro Bio Inc. Releases Overview of KRRO-121 RNA Editing Therapy for Ammonia Control

Reuters
·
Jan 27

Korro Bio Showcases KRRO-121 RNA Editing Program Progress

TIPRANKS
·
Jan 27

Korro Bio Hosts Virtual Analyst Day to Spotlight KRRO-121 for Hyperammonemia

Reuters
·
Jan 20

Korro Bio Updates Pipeline, Terminates KRRO-110 REWRITE Trial

TIPRANKS
·
Jan 16

Korro Bio Unveils Pipeline Advancements in RNA Editing for Genetic Medicines

Reuters
·
Jan 16

Korro Bio Boosts Executive Pay and Severance in New Agreement

Reuters
·
Dec 19, 2025

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Benzinga
·
Nov 14, 2025

Korro failure strengthens Wave Life Sciences position, says Jefferies

TIPRANKS
·
Nov 13, 2025

Korro Bio downgraded to Neutral from Overweight at Piper Sandler

TIPRANKS
·
Nov 13, 2025